GoAI
Get started
AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

ABCL

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$11.32

−$0.25 · -2.16%

Aug 21, 4:00 PM ET

ABCL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

2

Overpriced

Momentum

72

Gaining

Sentiment

63

Bullish

Risk resilience

51

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CA
CEO
Carl Hansen
Listed since
Dec 11, 2020
Employees
562

Market position

Day range

Current $11.32

52-week range

Current $11.32

Open
$11.60
Previous close
$11.57
Volume
4.55M
0.55× average
Average volume
8.23M
Average daily volume
Market cap
3.46B USD
Beta
1.19
Market reference 1
50-day average
$7.2092
+57.02% above average
200-day average
$4.7598
+137.83% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.04B USD
P/E (TTM)
-20.96×
P/B (TTM)
3.86×
P/S (TTM)
52.24×
EV / EBITDA
-6.97×
Earnings yield
-14.33%
Free cash flow yield
-17.04%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
74.95%
Operating margin
-340.25%
Net margin
-248.83%
Return on equity
-15.14%
Return on assets
-10.79%
Return on invested capital
-13.78%

Financial health

Debt / equity
0.15×
Current ratio
11.32×
Altman Z-score
5.02
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends219%-258%-734%-1211%Gross margin, FY2021: 87.87%Gross margin, FY2022: 86.31%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 61.64%Operating margin, FY2021: 54.48%Operating margin, FY2022: 44.60%Operating margin, FY2023: -623.82%Operating margin, FY2024: -1091.69%Operating margin, FY2025: -288.98%Net margin, FY2021: 40.90%Net margin, FY2022: 32.66%Net margin, FY2023: -385.00%Net margin, FY2024: -564.83%Net margin, FY2025: -194.88%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 87.87%. Gross margin FY2022 86.31%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 61.64%. Operating margin FY2021 54.48%. Operating margin FY2022 44.60%. Operating margin FY2023 -623.82%. Operating margin FY2024 -1091.69%. Operating margin FY2025 -288.98%. Net margin FY2021 40.90%. Net margin FY2022 32.66%. Net margin FY2023 -385.00%. Net margin FY2024 -564.83%. Net margin FY2025 -194.88%.

Income trends

Revenue

75.13M USD+160.56%

Operating income

−217.1M USD+31.03%

Net income

−146.41M USD+10.10%
Income trends across reported periods565.44M USD245.37M USD−74.71M USD−394.79M USDRevenue, FY2021: 375.2M USDRevenue, FY2022: 485.42M USDRevenue, FY2023: 38.03M USDRevenue, FY2024: 28.83M USDRevenue, FY2025: 75.13M USDOperating income, FY2021: 204.41M USDOperating income, FY2022: 216.51M USDOperating income, FY2023: −237.21M USDOperating income, FY2024: −314.77M USDOperating income, FY2025: −217.1M USDNet income, FY2021: 153.46M USDNet income, FY2022: 158.52M USDNet income, FY2023: −146.4M USDNet income, FY2024: −162.86M USDNet income, FY2025: −146.41M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 375.2M USD. Revenue FY2022 485.42M USD. Revenue FY2023 38.03M USD. Revenue FY2024 28.83M USD. Revenue FY2025 75.13M USD. Operating income FY2021 204.41M USD. Operating income FY2022 216.51M USD. Operating income FY2023 −237.21M USD. Operating income FY2024 −314.77M USD. Operating income FY2025 −217.1M USD. Net income FY2021 153.46M USD. Net income FY2022 158.52M USD. Net income FY2023 −146.4M USD. Net income FY2024 −162.86M USD. Net income FY2025 −146.41M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue75.13M USD28.83M USD38.03M USD485.42M USD375.2M USD
Cost of goods sold28.82M USD——66.44M USD45.52M USD
Gross profit46.31M USD28.83M USD38.03M USD418.99M USD329.69M USD
Research and development186.83M USD167.26M USD175.66M USD107.88M USD62.06M USD
Selling, general, and administrative76.58M USD85.49M USD75.18M USD66.76M USD48.76M USD
Operating expenses263.41M USD343.6M USD275.23M USD202.48M USD125.27M USD
Interest income28.33M USD38.47M USD42.25M USD16.08M USD3.33M USD
Interest expense———4.05M USD5.23M USD
Depreciation and amortization28.82M USD97M USD30.89M USD33.1M USD17.25M USD
Operating income−217.1M USD−314.77M USD−237.21M USD216.51M USD204.41M USD
Net income−146.41M USD−162.86M USD−146.4M USD158.52M USD153.46M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+13.55%
11 comparable reports
Latest EPS result
-0.18
Estimate -0.16 · Miss by 9.76%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-0.1-0.18-0.26Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.11, estimate -0.15, surprise +26.67%, Beat. Q2 2025, reported May 8, 2025: actual -0.15, estimate -0.17, surprise +11.76%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.12, estimate -0.17, surprise +29.41%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.19, estimate -0.17, surprise -11.76%, Miss. Q1 2026, reported Feb 24, 2026: actual -0.03, estimate -0.18, surprise +83.33%, Beat. Q2 2026, reported May 11, 2026: actual -0.14, estimate -0.22, surprise +36.36%, Beat. Q3 2026, reported Aug 5, 2026: actual -0.18, estimate -0.164, surprise -9.76%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.18, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates48.17M33.26M18.35M3.44MQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 5.05M USD, estimate 7.58M USD, surprise -33.37%, Miss. Q2 2025, reported May 8, 2025: actual 4.24M USD, estimate 7.31M USD, surprise -42.06%, Miss. Q3 2025, reported Aug 7, 2025: actual 17.08M USD, estimate 6.36M USD, surprise +168.63%, Beat. Q4 2025, reported Nov 6, 2025: actual 8.96M USD, estimate 6.31M USD, surprise +41.87%, Beat. Q1 2026, reported Feb 24, 2026: actual 44.9M USD, estimate 6.67M USD, surprise +572.89%, Beat. Q2 2026, reported May 11, 2026: actual 8.32M USD, estimate 5.41M USD, surprise +53.63%, Beat. Q3 2026, reported Aug 5, 2026: actual 4.05M USD, estimate 7.85M USD, surprise -48.39%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 5.32M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

12 ratings
Strong buy00%
Buy1192%
Hold18%
Sell00%
Strong sell00%

Recent analyst actions

6 institutions
Cantor FitzgeraldmaintainOverweight
Leerink PartnersdowngradeOutperformMarket Perform

ABCL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ABCL

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
20.34M
Weight
0.19%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Northern Lights Fund Trust III - Counterpoint Quantitative Equity ETF logoNorthern Lights Fund Trust III - Counterpoint Quantitative Equity ETFCPAI
Market value
12.92M
Weight
3.05%
AUM
377.71M USD
Expense ratio
0.75%
Price / 1D
$52.405+0.82%
State Street SPDR Portfolio Developed World ex-US ETF logoState Street SPDR Portfolio Developed World ex-US ETFSPDW
Market value
6.59M
Weight
0.02%
AUM
41.92B USD
Expense ratio
0.03%
Price / 1D
$52.02+0.79%
iShares Genomics Immunology and Healthcare ETF logoiShares Genomics Immunology and Healthcare ETFIDNA
Market value
6.24M
Weight
2.54%
AUM
250.38M USD
Expense ratio
0.47%
Price / 1D
$40.08+2.01%
State Street SPDR S&P International Small Cap ETF logoState Street SPDR S&P International Small Cap ETFGWX
Market value
1.94M
Weight
0.21%
AUM
927.26M USD
Expense ratio
0.40%
Price / 1D
$46.205+0.40%
Fidelity Nasdaq Composite Index ETF logoFidelity Nasdaq Composite Index ETFONEQ
Market value
1.57M
Weight
0.01%
AUM
10.35B USD
Expense ratio
0.21%
Price / 1D
$103.14+0.41%
Avantis U.S. Equity ETF logoAvantis U.S. Equity ETFAVUS
Market value
749.86K
Weight
0.01%
AUM
14.45B USD
Expense ratio
0.15%
Price / 1D
$130.59+0.52%
Virtus Biotech Clinical Trials ETF logoVirtus Biotech Clinical Trials ETFBBC
Market value
686.27K
Weight
1.34%
AUM
51.06M USD
Expense ratio
0.65%
Price / 1D
$54.415+1.01%

Continue in GoAI

Research ABCL

research.disclaimer